Oligonucleotides (ONs) comprise a rapidly growing class of therapeutics. In recent years, the
list of FDA-approved ON therapies has rapidly expanded. ONs are small (15–30 bp) …

The complexity of the tumor microenvironment presents significant challenges to cancer
therapy, while providing opportunities for targeted drug delivery. Using characteristic signals …

Accumulating research suggests that the tumor immune microenvironment (TIME) plays an
essential role in regulation of tumor growth and metastasis. The cellular and molecular …

RNA-based therapies, and siRNAs in particular, have attractive therapeutic potential for
cancer treatment due to their ability to silence genes that are imperative for tumor …

Peptide-oligonucleotide conjugates (POCs) represent one of the increasingly successful
albeit costly approaches to increasing the cellular uptake, tissue delivery, bioavailability …

Antisense oligonucleotides (ASOs) are incredibly versatile molecules that can be designed
to specifically target and modify RNA transcripts to slow down or halt rare genetic disease …

Introduction During past years, lipid nanoparticles (LNPs) have emerged as promising
carriers for RNA delivery, with several clinical trials focusing on both infectious diseases and …

Nanomedicines, emerging as an innovative category of cancer therapeutics, have garnered
increasing attention from both researchers and the broader public. However, despite this …

Simple Summary Neuroblastoma is one of the most diffuse and the deadliest cancer in
children. While many advances have been made in the last few decades to improve patients' …

Over the past few decades, the complexity of molecular entities being advanced for
therapeutic purposes has continued to evolve. A main propellent fueling innovation is the …